Kailera Therapeutics is trading at $12.80, up 5.18%, while the biotech sector is higher.
- Shares are rebounding from the November 5 close of $12.17. Provided sector context links the biotech rally to Moderna’s strong results and outlook, but does not establish a Kailera-specific catalyst.
- Kailera reported a $95.7 million third-quarter loss and reaffirmed cash runway into mid-2028 in its November 4 earnings release; available information does not establish that results caused the November 6 move.